证券代码：002317 编号：2023-004 广东众生药业股份有限公司投资者关系活动记录表 √□特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 类别 □新闻发布会 □路演活动 □现场参观 □一对一沟通 □其他（ ） 中国人保资产管理有限公司、兴业证券经济与金融研究院、 参与单位及人员 华鑫证券有限责任公司、金信基金管理有限公司等单位的分 析师、投资经理等 时间 2023 年 5 月 31 日 10:00～11:00 及 14:00～15:30 地点 广东众生药业股份有限公司会议室 形式 现场交流 1、董事会秘书 杨威 上市公司 接待人员 2、证券事务代表 陈子敏 3、证券业务经理 刘志 1、公司的基本情况。 答：公司是一家集药品研发、生产和销售为一体的高新技 术企业。公司秉承"以优质产品关爱生命，以优质服务健康大 众"的企业使命，以医药制造为核心主业，坚持研发创新和营 销创新双轮驱动的发展路径，矢志成为中国一流的医药健康 交流内容及具体 问答记录 产业集团。 公司不断通过自行研发和外部引进丰富产品管线和产品 群，依托医院、药店等主流渠道，同时积极拓展基层医疗机构、 线上销售，全力实现全 ...

证券代码：002317 编号：2023-003 广东众生药业股份有限公司投资者关系活动记录表 √□特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 类别 □新闻发布会 □路演活动 □现场参观 □一对一沟通 □其他（电话会议） 1、第一创业证券股份有限公司 杨芳 2、第一创业证券股份有限公司 傅晓云 3、第一创业证券股份有限公司 魏博慧 4、东海证券股份有限公司 姚文 5、国都创业投资有限责任公司 周玮 6、北京久银投资控股股份有限公司 相雨 7、深圳羿拓榕杨资产管理有限公司 朱戈光 8、深圳羿拓榕杨资产管理有限公司 郑迦皓 9、国泰租赁有限公司 王家利 参与单位名称 及人员姓名 10、国泰租赁有限公司 白金旭 11、红杉资本医疗基金 尚嘉琛 12、山东国惠基金管理有限公司 周扬 13、中融国际信托有限公司 王子琪 14、广东粤骏私募证券投资基金管理有限公司 陈燕敏 15、江西江投资本有限公司 王琪琦 16、华德国际金融控股有限公司 邹文 17、广州南粤基金集团有限公司 李正熹 18、深圳前海万亿兆资产管理有限公司 黄锐辉 19、上海乘舟投资管理有限公司 孙军 时间 2023 年 5 月 1 ...

证券代码：002317 编号：2023-002 广东众生药业股份有限公司投资者关系活动记录表 √□特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 类别 □新闻发布会 □路演活动 □现场参观 □一对一沟通 □其他（电话会议） 1、申万菱信基金管理有限公司 杨扬 参与单位名称 及人员姓名 2、上海鼎澄投资管理有限公司 霍炜 3、上海鼎澄投资管理有限公司 曹莉敏 时间 2023 年 5 月 10 日 10:00～12:00 地点 广东众生药业股份有限公司会议室 1、副董事长、高级副总裁 张玉冲 上市公司 接待人员 2、公司研发顾问 龙超峰 3、证券业务经理 刘志 1、公司2022年及2023年一季度的业绩情况。 答：公司继续围绕"中药为基、创新引领，聚焦特色的医 药健康企业"中期战略规划，主动适应、积极应对医药行业政 策和市场环境变化，持续优化经营策略，落实"全产品、全渠 道、全终端"的营销方针，战略规划有效落地，经营质量有所 提高。 投资者关系活动 主要内容介绍 2022年，公司实现营业收入267,615.16万元，同比增长 10.17%；实现归属于上市公司股东的净利润32,205.03万元 ...

Financial Performance - In Q1 2023, the company achieved operating revenue of CNY 746,765,187.01, representing a year-on-year increase of 10.50%[14] - The net profit attributable to shareholders of the listed company was CNY 139,376,205.22, reflecting a significant year-on-year growth of 86.86%[14] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 128,027,051.86, which is a slight increase of 1.47% compared to the previous year[14] - The basic earnings per share rose to CNY 0.17, an increase of 88.89% from CNY 0.09 in the same period last year[14] - The total operating revenue for Q1 2023 was ¥746,765,187.01, an increase of 10.5% compared to ¥675,794,415.22 in Q1 2022[39] - The net profit for Q1 2023 was ¥161,584,545.29, compared to ¥87,220,619.14 in Q1 2022, representing an increase of 85.2%[39] - The total profit for Q1 2023 was ¥161,536,199.78, compared to ¥86,884,589.30 in the same period last year, indicating a growth of about 85.8%[51] - The basic earnings per share for Q1 2023 was ¥0.17, up from ¥0.09 in Q1 2022, marking an increase of approximately 88.9%[51] Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -145,894,988.66, a decline of 668.32% compared to CNY 25,671,106.19 in the previous year[14] - The net cash flow from operating activities decreased significantly by 668.32% to approximately -¥145.89 million, mainly due to reduced cash inflow from bill discounting[25] - Cash and cash equivalents at the end of Q1 2023 amounted to ¥1,043,293,007.77, up from ¥927,671,556.82 at the beginning of the year, indicating a growth of 12.5%[36] - The company's total liabilities decreased from ¥1,958,820,439.83 to ¥1,781,825,176.09, a reduction of approximately 9.0%[49] - The total equity increased from ¥3,816,464,059.43 to ¥3,965,319,657.61, reflecting a growth of about 3.9%[49] - Total cash and cash equivalents at the end of the period amounted to 1,041,003,338.77 CNY, down from 1,152,024,850.15 CNY at the end of the previous period[59] Investments and Expenses - The company's trading financial assets decreased by 33.77% to approximately ¥225.63 million due to the maturity of bank wealth management products during the reporting period[25] - Long-term equity investments increased by 31.80% to approximately ¥5.63 million, attributed to higher equity investment income recognized under the equity method[25] - The company's intangible assets rose by 74.63% to approximately ¥454.74 million, driven by the capitalization of R&D expenditures[25] - Research and development expenses for Q1 2023 were ¥26,443,828.66, compared to ¥26,381,552.96 in Q1 2022, showing a slight increase[39] - The company reported a significant increase in investment income, reaching ¥7,708,534.84 in Q1 2023, compared to ¥4,869,233.57 in the previous year[39] - The company’s financial expenses decreased by 78.78% to approximately ¥2.91 million, mainly due to a reduction in interest expenses on financial liabilities[25] Strategic Initiatives - The company continues to implement a marketing strategy focused on "full product, full channel, full terminal" to drive growth[6] - The company has committed to enhancing communication and coordination with partners to efficiently advance project processes and improve data management and statistical analysis[20] - The company completed the enrollment of all cases for the Phase III clinical trial of the innovative drug ZSP1273 on March 15, 2023[45] - The company’s new drug, RAY1216 (brand name: Le Ru Ling®), received approval from the National Medical Products Administration (NMPA) for market launch on March 23, 2023[29] - The innovative drug RAY1216 received approval from the National Medical Products Administration for market launch on March 24, 2023[44] Shareholder and Equity Information - The equity attributable to shareholders of the listed company increased to CNY 3,795,935,764.27, marking a growth of 2.52% from CNY 3,702,739,955.97 at the end of the previous year[14] - The company’s minority shareholders' equity increased by 48.94% to approximately ¥169.38 million, primarily due to new investments received by subsidiaries[25] - The number of restricted stock units eligible for release in the first phase of the incentive plan was 2.28 million shares, accounting for approximately 0.28% of the total share capital[34] - The first lock-up period of the 2022 employee stock ownership plan was unlocked, allowing 2.28 million shares (40% of the total) to be released, which is 0.28% of the company's total share capital[45] - The company plans to issue shares to specific targets, with the approval from the China Securities Regulatory Commission received on April 28, 2023[33]

证券代码：002317 公告编号：2023-047 广东众生药业股份有限公司 关于举行 2022 年年度报告网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）2022 年年度报告及其摘要 于 2023 年 4 月 11 日在公司指定信息披露媒体《证券时报》和巨潮资讯网 （www.cninfo.com.cn）上披露。为便于投资者了解公司 2022 年度经营发展情况， 公司将于 2023 年 4 月 21 日（星期五）15:00～17:00 在全景网举行 2022 年年度 报告网上业绩说明会，本次说明会将采用网络远程的方式举行，投资者可登陆全 景网"投资者关系互动平台"（https://rs.p5w.net）参与本次说明会。 出席本次说明会的人员有：董事长、总裁陈永红先生，副董事长、高级副总 裁张玉冲女士，董事、副总裁、财务总监龙春华女士，独立董事牟小容女士。 为提升公司与投资者的交流效率和针对性，现就公司 2022 年年度业绩说明 会提前向投资者公开征集相关问题，广泛听取投资者的意见和建议。投资者可 ...

Innovation and Product Development - The company is recognized as a high-tech enterprise and has been included in the "2022 Top 100 Innovative Pharmaceutical Companies in China" and "2021 Top 100 Pharmaceutical Industries in China" lists[8]. - The company has a comprehensive product portfolio covering major disease areas such as ophthalmology, cardiovascular, respiratory, and digestive diseases, with a clear development path focusing on innovative drugs[8]. - The company’s innovative drug, Lai Ru Te Wei tablets, is the first oral medication for COVID-19 in China, demonstrating significant efficacy in reducing viral load and alleviating clinical symptoms[11]. - The company has successfully passed the consistency evaluation for three generic drugs, enhancing its competitive position in the market[11]. - The company has established a research and development team of over 400 people, with R&D investment consistently exceeding 8% of revenue[24]. - The company is actively expanding its product pipeline through both internal R&D and external partnerships, focusing on mainstream channels like hospitals and pharmacies[114]. - The company has a leading position in the development of innovative and improved drugs in respiratory, antiviral, oncology, and metabolic disease treatment areas[112]. - The company is focusing on a mid-term strategic plan that emphasizes traditional Chinese medicine and innovation to adapt to market changes[18]. - ZSP1601, an innovative drug for treating non-alcoholic steatohepatitis (NASH), has completed Phase Ib/IIa clinical trials, showing significant reductions in ALT and AST liver inflammation markers[40]. - RAY001, targeting metabolic diseases, is in preclinical development, while RAY002 has received approval for clinical trials[52]. - The company is actively developing high-quality health products based on core traditional Chinese medicine resources, targeting various consumer demographics and fostering a high repurchase rate for its health product line[144]. - The company is committed to continuous innovation in drug research and development, marketing models, and manufacturing technologies to drive long-term growth[182]. Financial Performance - The company achieved a revenue of 2,676.15 million yuan, representing a year-on-year growth of 10.17%[33]. - The net profit attributable to shareholders increased by 16.00% to 322.05 million yuan, while the net profit excluding non-recurring items rose by 0.27% to 300.42 million yuan[33]. - The total operating revenue for 2022 was CNY 2,676,151,617, representing a year-on-year increase of 10.17% compared to CNY 2,429,095,463.72 in 2021[69]. - The pharmaceutical manufacturing segment generated CNY 2,554,343,125.56, accounting for 95.45% of total revenue, with a year-on-year growth of 9.12%[69]. - The pharmaceutical trade segment saw a significant increase of 47.07%, reaching CNY 111,085,449.35, up from CNY 75,531,083.20 in 2021[69]. - The company reported a 62.87% increase in sales of raw materials and intermediates, totaling CNY 36,752,338.04[69]. - The net cash flow from operating activities decreased significantly by 89.87% to CNY 63,069,779 from CNY 622,766,288 in 2021[80]. - The total assets at the end of 2022 were CNY 5,775,284,499, reflecting a growth of 17.82% from CNY 4,901,980,878 at the end of 2021[98]. - The net assets attributable to shareholders increased by 6.53% to CNY 3,702,739,956 from CNY 3,475,652,726 in 2021[98]. - The basic earnings per share for 2022 were CNY 0.40, up 14.29% from CNY 0.35 in 2021[80]. - The diluted earnings per share also stood at CNY 0.40, marking a 14.29% increase from CNY 0.35 in the previous year[80]. - The company plans to distribute a cash dividend of CNY 2.00 per 10 shares (including tax) based on the total share capital as of December 31, 2022[86]. Market Strategy and Distribution - The sales model for the company’s pharmaceutical preparations is based on a buyout approach with distributors, ensuring a broad market reach[13]. - The company actively participates in industry exhibitions and utilizes online platforms to expand its customer base and promote its products[15]. - The company has established a nationwide, efficient distribution system to deliver products to hospitals and pharmacies, enhancing operational efficiency[131]. - The company has a complete industrial chain from raw materials to finished products, enhancing internal synergy and cost control[67]. - The company is committed to providing high-quality health solutions by integrating products with services, targeting diverse customer needs[114]. - The company has established a comprehensive marketing strategy focusing on "all products, all channels, and all terminals" to enhance market penetration[157]. - The company is actively pursuing digital marketing innovations to improve operational efficiency and market reach[161]. - The company expanded its market coverage to over 10,000 hospitals and more than 100,000 pharmacies nationwide[169]. - The company is actively participating in national and provincial alliance procurement to enhance market share and product distribution[170]. Research and Development - The company completed a clinical study involving over 5,000 participants for the treatment of ischemic stroke, enhancing the therapeutic and economic value of its products[18]. - The company has established strategic partnerships with universities and research institutions to enhance its research capabilities and innovation[16]. - The company is committed to integrating traditional Chinese medicine research with modern scientific methods, collaborating with key hospitals and research institutions[136]. - The company is exploring the development of classic traditional Chinese medicine formulas and hospital preparations, aligning with national policies encouraging innovation in traditional medicine[143]. - The company aims to enhance its upstream supply chain control by focusing on the cultivation and processing of traditional Chinese medicinal materials[137]. Challenges and Industry Trends - The company is facing rising operational costs due to various external factors, which is putting pressure on profitability[189]. - The pharmaceutical industry in China saw a decline in revenue, with a total of RMB 29,111.40 billion, down 1.6% year-on-year[122]. - The total profit for the pharmaceutical manufacturing industry decreased by 31.8% year-on-year, amounting to RMB 4,288.70 billion[122]. - The company experienced significant fluctuations in cash flow from operating activities, primarily due to the impact of bill discounting and early procurement of raw materials in Q4 2022[101]. Corporate Governance - The company has established a governance structure that includes independent directors, with three independent directors constituting one-third of the board, complying with legal and regulatory requirements[199]. - The company emphasizes equal rights for all shareholders during general meetings, ensuring compliance with relevant regulations and rules[199].